financetom
Business
financetom
/
Business
/
Why Is Tesla's Chinese Rival NIO Stock Diving Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Tesla's Chinese Rival NIO Stock Diving Today?
Mar 27, 2025 5:18 AM

NIO Inc. ( NIO ) shares traded lower premarket on Thursday. The stocks of automakers declined after the White House announced that President Trump would introduce new tariffs on auto imports during a press conference on Wednesday.

On Thursday, NIO disclosed its intention to offer up to 118.79 million Class A ordinary shares.

The company plans to use the net proceeds from this equity placement to fund research and development of smart electric vehicle technologies and new products, strengthen its balance sheet, and support general corporate purposes.

This week, the Chinese electric vehicle manufacturer informed investors to expect underwhelming first-quarter results.

The company reportedly expects to deliver up to 43,000 vehicles by March 31, with a projected revenue of approximately 12.9 billion yuan ($1.8 billion).

Nio has also received funding from strategic investors, including a 3.3 billion yuan (~$455 million) investment from Hefei government-backed funds and a $2.94 billion capital injection from Abu Dhabi’s CYVN Holdings in 2023.

Last week, the company reported fiscal fourth-quarter revenue of 19.70 billion Chinese yuan ($2.70 billion), up 15.2% year-over-year and up 5.5% sequentially. Analysts, on average, estimated revenue of $2.85 billion for the quarter.

NIO reported an adjusted loss per share per ADS of 3.17 Chinese yuan or 43 cent loss compared to a 2.81 Chinese yuan loss in the year-ago quarter. Analysts had called for a loss of 42 cents per ADS.

Price Action: NIO shares are down 7.58% at $3.90 premarket at the last check Thursday.

Read Next:

Gordon Johnson Dismisses ‘Don’t Bet Against Elon Musk’ Narrative, Says Tesla Bears Have ‘Won Big’ Since 2022

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Procter & Gamble Insider Sold Shares Worth $5,253,549, According to a Recent SEC Filing
Procter & Gamble Insider Sold Shares Worth $5,253,549, According to a Recent SEC Filing
May 7, 2024
09:29 AM EDT, 05/07/2024 (MT Newswires) -- Shailesh Jejurikar, Chief Operating Officer, on May 06, 2024, sold 31,859 shares in Procter & Gamble ( PG ) for $5,253,549. Following the Form 4 filing with the SEC, Jejurikar has control over a total of 50,006 shares of the company, with 9,739 shares held directly and 40,267 shares controlled indirectly. SEC Filing:...
BRIEF-IMAC Holdings Acquires Assets Of Theralink To Continue Precision Medicine Business
BRIEF-IMAC Holdings Acquires Assets Of Theralink To Continue Precision Medicine Business
May 7, 2024
May 7 (Reuters) - IMAC Holdings Inc ( BACK ): * IMAC HOLDINGS ACQUIRES ASSETS OF THERALINK TO CONTINUE PRECISION MEDICINE BUSINESS * IMAC HOLDINGS INC ( BACK ): IN PROCESS OF TRANSITIONING KEY EMPLOYEES TO STABILIZE BUSINESS OPERATIONS * IMAC HOLDINGS INC ( BACK ): ON MAY 6, BACK, IMAC MERGER SUB AND THERALINK ENTERED INTO TERMINATION AGREEMENT Source...
BRIEF-Global Water Resources To Acquire Seven Water Systems From Tucson Water, Adding 2,200 Customer Connections
BRIEF-Global Water Resources To Acquire Seven Water Systems From Tucson Water, Adding 2,200 Customer Connections
May 7, 2024
May 7 (Reuters) - Global Water Resources Inc ( GWRS ): * GLOBAL WATER RESOURCES TO ACQUIRE SEVEN WATER SYSTEMS FROM TUCSON WATER, ADDING 2,200 CUSTOMER CONNECTIONS Source text for Eikon: Further company coverage: ...
BRIEF-Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
BRIEF-Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 7, 2024
May 7 (Reuters) - Myriad Genetics Inc ( MYGN ): * MYRIAD GENETICS ANNOUNCES REORGANIZATION OF EUROPEAN OPERATIONS AND SALE OF ENDOPREDICT BUSINESS * MYRIAD GENETICS INC ( MYGN ): TO SELL ITS ENDOPREDICT BUSINESS TO EUROBIO SCIENTIFIC * MYRIAD GENETICS INC ( MYGN ): WILL LICENSE EUROBIO RIGHT TO SELL PROLARIS IN VITRO DIAGNOSTIC KITS OUTSIDE U.S. Source text...
Copyright 2023-2026 - www.financetom.com All Rights Reserved